entertainment -WSS

entertainment

author：fashion 2025-10-02 23:45:42 - browse：57

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Being 'nonadherent' patient made me a more empathetic doctor

leisure time

WSS

Canadians with cystic fibrosis outlive Americans by a decade

Ventyx halts psoriasis drug development after lackluster trial results

Use doctors trained outside the U.S. to ease the physician shortage

Prescription digital therapeutics are key to pharma’s future

The wait for US passports is creating travel purgatory and snarling summer plans

Lupron, used to halt puberty in children, may cause lasting health problems

focus

entertainment

entertainment

Jerome Adams on the need for new antivirals for Covid

Prescription digital therapeutics are key to pharma’s future

As demand for Covid shots wanes, Moderna seeks its next success

Hubble vs. James Webb telescope images: See the difference

The cancer drug shortage isn’t new — and neither are the solutions

Top Ukrainian generals say counteroffensive is 'going to plan' as losses mount

The high cost of giving birth even with insurance

Medicare’s new pay boost for primary care is angering specialists

Heart attack and stroke risk calculators need revising

Security flaws in third

focus

Lupron, used to halt puberty in children, may cause lasting health problems

How state and local governments are sidelining science

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Fatty liver disease was alleviated by Lilly’s ‘triple

How Robert F. Kennedy Jr. distorted vaccine science

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Wikipedia

leisure time

explore

hotspot